cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30031225
title: Supplementary Material for: Therapeutic Effects and Safety of Mirtazapine for Insomnia in Major Depressive Disorder: Findings from a 6-Week Open-Label Pre- and Post-Intervention Study

description: Introduction: Insomnia is one of the most common symptoms of depression, estimated to occur in approximately 75% of adult patients with depression, and it may persist even after remission from depressive episodes. Our objectives were to evaluate the efficacy of mirtazapine in reducing insomnia and depression symptom severity, assess side effects, and compare quality of life before and after intervention in major depressive disorder (MDD) patients with insomnia.

Methods: This was a single-center, prospective, open-label, quasi-experimental pre-post intervention trial of six weeks. The Hamilton Depression Rating Scale (HDRS), Insomnia Severity Index (ISI), Antidepressant Side-Effect Checklist (ASEC), and World Health Organization Quality of Life (WHOQOL-BREF) tools were used during the assessment.

Results: Out of the 135 recruited patients, 109 (80.7%) completed the trial. On day 14, with a mean dose of 18.9 mg/day, 24.8% of patients experienced remission for insomnia, while 7.3% showed remission for depression. By day 42, with a mean dose of 18.7 mg/day, these figures increased to 62.4% for insomnia and 41.3% for depression. The reduction in the ISI score (mean±SD) from baseline to day 14 and day 42 was 8.74±6.16 and 13.55±5.32, respectively. Similarly, the reduction in the HDRS score from baseline on day 14 and 42 was 10.30±6.89 and 17.78±6.26, respectively. The most commonly reported adverse effects (&gt;10%) included increased appetite, drowsiness, weight gain, dry mouth, headache, and constipation. Regarding QoL, the differences were significant for all four domains with the highest improvement observed in the physical (mean difference 25.67±13.95) and psychological domains (mean difference 26.35±16.42) of QoL. 
 
Conclusion: Mirtazapine treatment was associated with significant improvements in depression, insomnia, and all QoL parameters, with increased appetite and weight gain being the most common adverse effects. Further randomized controlled comparator studies will be beneficial for healthcare providers to improve the clinical care of MDD patients with insomnia.
DOI: 10.6084/m9.figshare.30031228
title: Supplementary Material for: Adverse event following change in brachytherapy plaque cleaning chemicals: a case series

description: Introduction: 
The brachytherapy plaques used for uveal melanoma treatment are reused following sterilization processes. In this case series, we report patients with adverse reaction following a new cleaning procedure for brachytherapy plaques.
Case Presentations:
The brachytherapy plaque sewn on the outer eyewall would be removed following the delivery of calculated radiation dose. They are reused following standard calibration testing and sterilization processes. From September 2021 to January 2022, 6 patients treated with Ruthenium-106 plaque brachytherapy presented with severe unilateral pain, eyelid swelling and conjunctival injection with hemorrhage 1-2 days following plaque insertion. The surgeons observed a frosted appearance of the plaques in contrast to the normal shiny look during removal. The unusual severe post-operative reactions and the frosted appearance of plaques led to further investigations. A change in sterilization procedures with the use of LifeCleanTM instead of PerasafeTM was noticed. Ruthenium-106 brachytherapy plaques contain a uniformly distributed radioactive source covered by a thin silver shield. A test was performed by using two plates of pure silver that underwent its respective cleaning procedure using either PerasafeTM or LifeCleanTM.
Conclusion:
The test results demonstrated formation of silver chloride with LifeCleanTM, while no such formation with PerasafeTM. We did not observe any new cases of severe post-operative reaction or frosting of plaques after changing back to PerasafeTM. Chlorine salt deposits probably contributed to severe inflammatory reaction of ocular surface.
DOI: 10.6084/m9.figshare.30031228.v1
title: Supplementary Material for: Adverse event following change in brachytherapy plaque cleaning chemicals: a case series

description: Introduction: 
The brachytherapy plaques used for uveal melanoma treatment are reused following sterilization processes. In this case series, we report patients with adverse reaction following a new cleaning procedure for brachytherapy plaques.
Case Presentations:
The brachytherapy plaque sewn on the outer eyewall would be removed following the delivery of calculated radiation dose. They are reused following standard calibration testing and sterilization processes. From September 2021 to January 2022, 6 patients treated with Ruthenium-106 plaque brachytherapy presented with severe unilateral pain, eyelid swelling and conjunctival injection with hemorrhage 1-2 days following plaque insertion. The surgeons observed a frosted appearance of the plaques in contrast to the normal shiny look during removal. The unusual severe post-operative reactions and the frosted appearance of plaques led to further investigations. A change in sterilization procedures with the use of LifeCleanTM instead of PerasafeTM was noticed. Ruthenium-106 brachytherapy plaques contain a uniformly distributed radioactive source covered by a thin silver shield. A test was performed by using two plates of pure silver that underwent its respective cleaning procedure using either PerasafeTM or LifeCleanTM.
Conclusion:
The test results demonstrated formation of silver chloride with LifeCleanTM, while no such formation with PerasafeTM. We did not observe any new cases of severe post-operative reaction or frosting of plaques after changing back to PerasafeTM. Chlorine salt deposits probably contributed to severe inflammatory reaction of ocular surface.
DOI: 10.6084/m9.figshare.30031231
title: Supplementary Material for: Hemolytic Disease of the Fetus and Newborn due to an anti- LU1 (anti-Lua) alloantibody, case report

description: Many erythrocyte antibodies have been reported to cause hemolytic disease of the fetus and newborn (HDFN), but Lutheran (LU) alloantibodies are normally not involved in HDFN.
Here we report the obstetrical history of a 29-year-old women with pregnancy complications due to an anti-LU1 antibody causing fetal anemia and the successful treatment with intrauterine transfusion (IUT). 
Non-immune hematological causes for fetal anemia and the presence of further alloantibodies, notably antibodies against low frequent antigens, could be ruled out. 
Swiss national immunohematology reference laboratory in Bern carried out a monocyte monolayer assay (MMA). The monocyte index (MI) was &gt;20%, indicating the presence of a clinical relevant antibody. 
The diagnosis, acute management, and follow‐up of neonates with fetal anemia still represent an important area of activity for maternity/neonatal services. To our knowledge this is the first reported case of HDFN due to an anti-LU1 antibody requiring IUT.
DOI: 10.6084/m9.figshare.30031231.v1
title: Supplementary Material for: Hemolytic Disease of the Fetus and Newborn due to an anti- LU1 (anti-Lua) alloantibody, case report

description: Many erythrocyte antibodies have been reported to cause hemolytic disease of the fetus and newborn (HDFN), but Lutheran (LU) alloantibodies are normally not involved in HDFN.
Here we report the obstetrical history of a 29-year-old women with pregnancy complications due to an anti-LU1 antibody causing fetal anemia and the successful treatment with intrauterine transfusion (IUT). 
Non-immune hematological causes for fetal anemia and the presence of further alloantibodies, notably antibodies against low frequent antigens, could be ruled out. 
Swiss national immunohematology reference laboratory in Bern carried out a monocyte monolayer assay (MMA). The monocyte index (MI) was &gt;20%, indicating the presence of a clinical relevant antibody. 
The diagnosis, acute management, and follow‐up of neonates with fetal anemia still represent an important area of activity for maternity/neonatal services. To our knowledge this is the first reported case of HDFN due to an anti-LU1 antibody requiring IUT.
DOI: 10.15468/dl.rjq6v4
title: Occurrence Download

description: A dataset containing 22419 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Europe",
 "CoordinateUncertaintyInMeters 0.0-10.0",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Quercus",
 "Year 2024-2024"
 ]
}

 The dataset includes 22419 records from 33 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019030-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30031234
title: Supplementary Material for: Deep Venous Thrombosis as the Sentinel Event Unmasking a Uterine Leiomyosarcoma in a Postmenopausal Woman: A Case Report and Review of the Literature

description: Introduction
Uterine tumors are classified as benign or malignant, with leiomyomas being the most common benign type and leiomyosarcomas (LMS) being a rare but aggressive form of uterine sarcoma. The clinical similarity between these two tumor types often makes preoperative differentiation challenging, necessitating surgery for a definitive diagnosis. LMS are highly aggressive with a poor prognosis. We present the case of a 60-year-old woman whose uterine leiomyosarcoma was initially diagnosed as a benign myoma, with deep venous thrombosis (DVT) serving as an atypical presenting sign of her underlying malignancy.
Case Presentation
A 60-year-old postmenopausal woman presented with a large, progressively enlarging abdominal mass, which had been identified five years prior as a probable leiomyoma. She initially declined surgery but was readmitted one month later with a DVT in her left leg, which was attributed to the compressive effect of the large pelvic mass. The patient underwent a total abdominal hysterectomy. Histopathological and immunohistochemical analysis of the 21 cm uterine tumor confirmed a high-grade leiomyosarcoma. Subsequent staging scans revealed Stage IVB metastatic disease in her lungs, liver, and bones. The patient was transitioned to palliative care and passed away six weeks after her surgery.
Conclusion
Uterine leiomyosarcomas can deceptively mimic benign leiomyomas, which may lead to significant diagnostic delays and contribute to poor outcomes. This case highlights that an atypical presentation, such as an idiopathic deep vein thrombosis, should heighten clinical suspicion for an underlying pelvic malignancy, even in the absence of typical gynecological symptoms. Accurate and timely diagnosis is critical and ultimately depends on definitive histopathological evaluation, underscoring the highly aggressive nature and significant mortality associated with this rare cancer.
DOI: 10.6084/m9.figshare.30031234.v1
title: Supplementary Material for: Deep Venous Thrombosis as the Sentinel Event Unmasking a Uterine Leiomyosarcoma in a Postmenopausal Woman: A Case Report and Review of the Literature

description: Introduction
Uterine tumors are classified as benign or malignant, with leiomyomas being the most common benign type and leiomyosarcomas (LMS) being a rare but aggressive form of uterine sarcoma. The clinical similarity between these two tumor types often makes preoperative differentiation challenging, necessitating surgery for a definitive diagnosis. LMS are highly aggressive with a poor prognosis. We present the case of a 60-year-old woman whose uterine leiomyosarcoma was initially diagnosed as a benign myoma, with deep venous thrombosis (DVT) serving as an atypical presenting sign of her underlying malignancy.
Case Presentation
A 60-year-old postmenopausal woman presented with a large, progressively enlarging abdominal mass, which had been identified five years prior as a probable leiomyoma. She initially declined surgery but was readmitted one month later with a DVT in her left leg, which was attributed to the compressive effect of the large pelvic mass. The patient underwent a total abdominal hysterectomy. Histopathological and immunohistochemical analysis of the 21 cm uterine tumor confirmed a high-grade leiomyosarcoma. Subsequent staging scans revealed Stage IVB metastatic disease in her lungs, liver, and bones. The patient was transitioned to palliative care and passed away six weeks after her surgery.
Conclusion
Uterine leiomyosarcomas can deceptively mimic benign leiomyomas, which may lead to significant diagnostic delays and contribute to poor outcomes. This case highlights that an atypical presentation, such as an idiopathic deep vein thrombosis, should heighten clinical suspicion for an underlying pelvic malignancy, even in the absence of typical gynecological symptoms. Accurate and timely diagnosis is critical and ultimately depends on definitive histopathological evaluation, underscoring the highly aggressive nature and significant mortality associated with this rare cancer.
DOI: 10.6084/m9.figshare.30031237.v1
title: Supplementary Material for: Predictors of Quality of Life in Myasthenia Gravis Patients from Southwestern China: Validation of Clinical and Socioenvironmental Determinants

description: Introduction: Myasthenia gravis (MG) presents a substantial clinical burden, characterized by increased incidence of myasthenic crises, heterogeneity in treatment response, significant functional impairment, and gradually increasing mortality rates with marked geographical heterogeneity across China. While improving quality of life (QOL) is the focus of MG management, multifactorial determinants of QOL impairment remain unclear, especially in socioeconomically underrepresented regions, particularly Southwestern China. This study aimed to explore myasthenia-specific risk factors for QOL and develop a parsimonious prediction model. Methods: This study performed univariate and multivariate regression analyses on 310 myasthenia gravis (MG) patients diagnosed at the First Affiliated Hospital of Chongqing Medical University between January 2022 and February 2025 from Southwestern China. The QOL of patients was evaluated with the 15-item Myasthenia Gravis Quality of Life (MG-QOL15). Disease severity was evaluated with current Myasthenia Gravis Foundation of America (MGFA) classification, MG-related activities of daily living (MG-ADL) score and quantitative myasthenia gravis (QMG) score. Relevant clinical and demographic data were included in the analysis. Results: In the analysis of basic characteristics, higher ADL (P&lt;0.001), worse MGFA classification (P&lt;0.001), lower education level (P=0.006), thymic abnormalities (P=0.004), and treatment (P=0.003) were significantly correlated with poor QOL. However, factors such as age of onset, gender, and antibody status showed no significant impact. The multivariate models (Model 1-6) further confirmed that MG-ADL (OR = 8.397), QMG score (OR = 4.357), MGFA classification, and thymus histology (thymic hyperplasia OR = 4.505, thymoma OR = 2.472) were independent risk factors for QOL. Corticosteroids combined with immunotherapy was found to significantly improve QOL compared to monotherapy. Model validation indicated that Model 5, which incorporates MG-ADL, MGFA classification, thymus histology, and education level, had the optimal overall performance (AUC = 0.835, specificity 0.917), balancing predictive accuracy and clinical applicability. Conclusion: By identifying key predictors, including clinical severity, thymic abnormalities, and education level, this study developed a multidimensional prediction model for QOL in MG patients.
DOI: 10.6084/m9.figshare.30031237
title: Supplementary Material for: Predictors of Quality of Life in Myasthenia Gravis Patients from Southwestern China: Validation of Clinical and Socioenvironmental Determinants

description: Introduction: Myasthenia gravis (MG) presents a substantial clinical burden, characterized by increased incidence of myasthenic crises, heterogeneity in treatment response, significant functional impairment, and gradually increasing mortality rates with marked geographical heterogeneity across China. While improving quality of life (QOL) is the focus of MG management, multifactorial determinants of QOL impairment remain unclear, especially in socioeconomically underrepresented regions, particularly Southwestern China. This study aimed to explore myasthenia-specific risk factors for QOL and develop a parsimonious prediction model. Methods: This study performed univariate and multivariate regression analyses on 310 myasthenia gravis (MG) patients diagnosed at the First Affiliated Hospital of Chongqing Medical University between January 2022 and February 2025 from Southwestern China. The QOL of patients was evaluated with the 15-item Myasthenia Gravis Quality of Life (MG-QOL15). Disease severity was evaluated with current Myasthenia Gravis Foundation of America (MGFA) classification, MG-related activities of daily living (MG-ADL) score and quantitative myasthenia gravis (QMG) score. Relevant clinical and demographic data were included in the analysis. Results: In the analysis of basic characteristics, higher ADL (P&lt;0.001), worse MGFA classification (P&lt;0.001), lower education level (P=0.006), thymic abnormalities (P=0.004), and treatment (P=0.003) were significantly correlated with poor QOL. However, factors such as age of onset, gender, and antibody status showed no significant impact. The multivariate models (Model 1-6) further confirmed that MG-ADL (OR = 8.397), QMG score (OR = 4.357), MGFA classification, and thymus histology (thymic hyperplasia OR = 4.505, thymoma OR = 2.472) were independent risk factors for QOL. Corticosteroids combined with immunotherapy was found to significantly improve QOL compared to monotherapy. Model validation indicated that Model 5, which incorporates MG-ADL, MGFA classification, thymus histology, and education level, had the optimal overall performance (AUC = 0.835, specificity 0.917), balancing predictive accuracy and clinical applicability. Conclusion: By identifying key predictors, including clinical severity, thymic abnormalities, and education level, this study developed a multidimensional prediction model for QOL in MG patients.
DOI: 10.6084/m9.figshare.30031201.v1
title: <b>Schengen in Crisis? Positions of Member States Reimposing Internal Border Controls</b>

description: Dataset for the article <b>Schengen in Crisis? Positions of Member States Reimposing Internal Border Controls</b>
DOI: 10.6084/m9.figshare.30031201
title: <b>Schengen in Crisis? Positions of Member States Reimposing Internal Border Controls</b>

description: Dataset for the article <b>Schengen in Crisis? Positions of Member States Reimposing Internal Border Controls</b>
DOI: 10.5517/ccdc.csd.cc1nt0r7
title: CCDC 1543389: Experimental Crystal Structure Determination

description: Related Article: Irshad Ahmad Bhat, Iruthayaraj Avinash, Ganapathi Anantharaman|2019|Organometallics|38|1699|doi:10.1021/acs.organomet.8b00878
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc1nt0t9
title: CCDC 1543391: Experimental Crystal Structure Determination

description: Related Article: Irshad Ahmad Bhat, Iruthayaraj Avinash, Ganapathi Anantharaman|2019|Organometallics|38|1699|doi:10.1021/acs.organomet.8b00878
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc203rb7
title: CCDC 1850648: Experimental Crystal Structure Determination

description: Related Article: Caitilín McManus, Prasenjit Mondal, Marta Lovisari, Brendan Twamley, Aidan R. McDonald|2019|Inorg.Chem.|58|4515|doi:10.1021/acs.inorgchem.9b00055
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc20c1v9
title: CCDC 1857670: Experimental Crystal Structure Determination

description: Related Article: Chenglong Deng|2018|CSD Communication|||
description: Related Article: Wen-Yu Mou, Tao Li, Bin Xie, Dong-Liang Zhang, Chuan Lai, Cheng-Long Deng, Jia-Xi Cao, Xiao-Xue Bai, Xiao-Qiang Liu|2020|Inorg.Chim.Acta|507|119587|doi:10.1016/j.ica.2020.119587
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc20c1wb
title: CCDC 1857671: Experimental Crystal Structure Determination

description: Related Article: Chenglong Deng|2018|CSD Communication|||
description: Related Article: Wen-Yu Mou, Tao Li, Bin Xie, Dong-Liang Zhang, Chuan Lai, Cheng-Long Deng, Jia-Xi Cao, Xiao-Xue Bai, Xiao-Qiang Liu|2020|Inorg.Chim.Acta|507|119587|doi:10.1016/j.ica.2020.119587
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc20c1xc
title: CCDC 1857672: Experimental Crystal Structure Determination

description: Related Article: Chenglong Deng|2018|CSD Communication|||
description: Related Article: Wen-Yu Mou, Tao Li, Bin Xie, Dong-Liang Zhang, Chuan Lai, Cheng-Long Deng, Jia-Xi Cao, Xiao-Xue Bai, Xiao-Qiang Liu|2020|Inorg.Chim.Acta|507|119587|doi:10.1016/j.ica.2020.119587
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc20qf17
title: CCDC 1868588: Experimental Crystal Structure Determination

description: Related Article: Sebastian M. Krajewski, Aaron S. Crossman, Eser S. Akturk, Tim Suhrbier, Steven J. Scappaticci, Maxwell W. Staab, Michael P. Marshak|2019|Dalton Trans.|48|10714|doi:10.1039/C9DT02293G
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.